Drug Guidance

Review of cancer drugs for previously treated advanced gastric cancer

Drug guidance

Review of cancer drugs for acute lymphoblastic leukaemia

Drug guidance

Review of cancer drugs for treating advanced urothelial carcinoma

Drug guidance

Blinatumomab for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia

Drug guidance

Nivolumab for treating gastroesophageal cancers

Drug guidance

Update of MOH List of Subsidised Drugs to include treatments for various cancer conditions

Drug guidance

Nirmatrelvir and ritonavir combination for treating mild-to-moderate COVID-19

Drug guidance

Toripalimab for first-line systemic treatment of recurrent or metastatic nasopharyngeal carcinoma

-

Drug guidance

Nivolumab in combination with ipilimumab and chemotherapy for untreated metastatic or recurrent non-small-cell lung cancer in patients whose tumours express PD-L1 with a tumour proportion score <1% with no EGFR or ALK genomic tumour mutations

-

Drug Guidance

Momelotinib for treating myelofibrosis in patients with moderate to severe anaemia

-

Drug guidance